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A 38-year-old right-handed lady presented with a 1-month
history of seizures. Her attacks began with a sudden wave of
dizziness, followed by a feeling of unsteadiness as if she might fall;
associated with sensory disturbance down the right side of her
face, right arm and right leg. She denied any limb paralysis or
shaking. The initial phase was followed by loss of recognition of her
right arm and if standing she would fall.
She gave a history of epileptic seizures between the ages of six
months to ﬁve years. She would wobble, appear strange and
stare, be vacant and fall. She took Phenobarbitone during this
period. She experienced two generalised tonic clonic seizures as a
teenager. The ﬁrst seizure occurred at the age of eleven and the
second one at the age of fourteen and they were both precipitated
by visual stimuli. The ﬁrst attack happened when she was lying
on the sofa with her head hanging over the back of it whilst
watching TV upside down, the second one, she had just turned
the TV on and was about a foot away when the bright display
came on. She quickly turned away when she felt bright ﬂashing
lights across her right visual ﬁeld, the same ones that had
precipitated her seizure three years earlier. She also admitted to a
feeling of ﬂutters over her head during both events. She took
sodium valproate until the age of twenty-three with no further
seizures. No brain imaging or EEG was done after the childhood
seizures.
Magnetic Resonance Image (MRI) (Fig. 1) revealed three
separate lesions in the left frontal, left parietal and left occipital
lobes. Along with MR spectroscopy a radiological diagnosis of low-
grade multicentric glioma was made.* Corresponding author. Tel.: +44 7973110337.
E-mail address: hamandik@cf.ac.uk (K. Hamandi).
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http://dx.doi.org/10.1016/j.seizure.2013.02.018She underwent a left occipital mini-craniotomy and excision of
occipital tumour and a left-frontal mini craniotomy and biopsy of
the frontal space lesion. No intervention was carried out on the
parietal lesion, given its close proximity to the sensorimotor cortex
and normal MR spectroscopy. Post operatively there was no visual
ﬁeld deﬁcit. She experienced attacks of ﬂashing lights on her right
visual ﬁeld, with several episodes per month lasting minutes. She
was treated with carbamazepine post-operatively. Seizures
stopped eleven months after the operation and she remains
seizure free, having withdrawn all antiepileptic medication for
three years. Three-year follow-up MRI shows no new changes,
annual follow up MRI continues.
We discuss the radiological, neuropathological and genetic
ﬁndings encountered and review the literature.
2. Neuropathology
The specimen obtained from the occipital lesion (Fig. 2)
revealed a large fragment of cerebral cortex with areas inﬁltrated
by tumour cells consistent with a low-grade glioma with some
features of an oligodendroglioma WHO grade II.1 There was no
evidence of necrosis; mitotic ﬁgures, blood vessel wall changes or
ganglionic differentiation and the surrounding cerebral cortex did
not contain evidence of cortical dysplasia or heterotopia.
Immunohistochemistry with anti-Ki-67 (a marker of cell prolifer-
ation) showed a low proliferation index, anti-GFAP (Glial ﬁbrillary
acidic protein) demonstrated ﬁbrillary processes. Tumour necrosis
and vessel wall changes were absent. Similar histological and
immunohistological changes were found in the frontal lobe
specimen (Fig. 2). Both specimens were regarded as LGG WHO II
with predominantly oligodendroglial features, but with an
astrocytic component (GFAP positive staining). There was no
evidence of ganglionic differentiation with anti-synaptophysin or
neuroﬁlament antibodies.
3. PCR analysis
DNA from occipital and frontal specimens showed loss of
heterozygosity (LOH) in 1p/19q, and loss of 10q and 7p. Both the
occipital and frontal sections showed mutations in the isocitrate
dehydrogenase 1 (IDH1) gene and no mutation of the IDH2 gene.
These ﬁndings are consistent with low-grade glioma.vier Ltd. All rights reserved.
Fig. 1. MRI brain: (A) axial T2 showing occipital and frontal lesions, (B) axial T2 showing parietal lesion, (C) fast spoiled gradient echo (FSPGR) showing frontal and occipital
lesions, (D) FSPGR showing parietal lesion. There was no enhancement to suggest high grade but there was some mass effect present at the time. MRI spectroscopy: (E) frontal
lesion showed relative reduction in NAA compared to creatine and an increase in choline compared to creatine. NAA is a marker for normal neurones and axons, creatine is an
internal standard and an increase in choline reﬂects an increase in cellular division. Spectroscopy of the occipital (F) was close to normal, supported by minimal reduction in
NAA from the occipital lesion but no elevation in myo-inositol or choline. The parietal lesion had essentially normal spectroscopy.
P. Garcia Pulido et al. / Seizure 22 (2013) 480–482 4814. Discussion
Low-grade gliomas are primary brain tumours that arise from
glial cells. They are separated according to the glial type from which
they arise, astrocytoma or oligodendrogioma. The World Health
Organisation (WHO) classiﬁcation divides astrocytoma into four
grades (I–IV), from least to most malignant. Oligodendrogiomas areFig. 2. Frontal (A)–(C) and occipital (D)–(F) tumour biopsies. A scale bar has been added 2
sections showing detailed cellular morphology, similar morphology is seen in both. B sho
and E Anti-GFAP demonstrates ﬁbrillary staining pattern. C/F Ki67 labelling demonstraclassiﬁed, as grade II.1 Low-grade gliomas are often mistakenly
thought of as benign neoplasm and their association with
neurological morbidity and mortality as well as their potential for
anaplastic transformation disregarded.2 Moreover, the optimum
management of this type of tumour continues to be a matter of
individual clinical judgement and subsequent debate due to the lack
of sufﬁcient data to inform the decision-making process.30 microns in length for each image. A/D Haemotoxylin & Eosin stained parafﬁn wax
ws anti-GFAP staining of ﬁbrillary processes but not all nuclei are positively stained
ting a low proliferation index similar in both tumours.
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been previously reported. They can be grouped in two main
categories: multicentric and multifocal.4 The main difference is
their mechanism of spread. Multifocal gliomas disseminate from
a primary site5 along nerve ﬁbre bundles, CSF channels and blood.
Multicentric gliomas consist of separate entities, in different
lobes or hemispheres, and show no spread or metastasis.6 The
exact incidence of multiple gliomas is unknown, a range between
0.5% and 20% has been quoted in previous reports,6 with most
reports describing two lesions in either separate or the same lobe.
Whilst rare cases of oligodendrocytic gliomatosis cerebri have
been reported in the literature,7 the lack of white matter
involvement in imaging and pathology, stable neurological status
and survival interval, make this alternative diagnosis unlikely. To
the best of our knowledge, this is the ﬁrst report of a case
involving three separate low-grade supratentorial lesions in three
separate lobes, two with the same histopathology and PCR
analysis.
The morphological features in each tumour are of low grade
gliomas LGG2 (World Health Organisation II) of mainly oligoden-
droglial sub-type, but owing to the presence of positive anti-GFAP
raises the possibility of a mixed tumour of oligodendroglial and
astrocytic differentiation (Fig. 2). The loss of heterozygosity (LOH)
1p/19q supports the histological and immunohistochemical data;
oligodendrogliomas are more frequently associated with LOH 1p/
19q than the oligoastrocytomas.2,8,9 The LOH 10q/7p is unexpected
but this test was repeated and considered robust.
IDH1 mutations occur mainly in low-grade gliomas (astrocyto-
mas and oligodendrogliomas) and are retained during tumour
progression.10 It also helps distinguish low-grade gliomas from
other tumour entities where the mutation does not occur, or where
it occurs very rarely.10 The presence of an IDH1 mutation also has
an impact on prognosis, with median survival being 3.8 years for
patients with mutated IDH1, as compared to 1.1 years for patients
with wild-type IDH.10 Both the occipital and frontal sections
showed mutation of the IDH1 gene in our patient, which would be
consistent with her stable clinical status so far.
The previous history of occipital onset seizures with secondary
generalisation as a teenager in our patient, suggests an occipital
lesion may have been present from early teens, and the earlier
childhood seizures may have also been lesional; this is notpossible to corroborate, as the patient did not have brain imaging
at the time.
5. Conclusion
Multicentric low-grade oligodendrogliomas are uncommon
and despite their initially insidious clinical presentation, they
retain a potential for malignant transformation. Our case is
unusual given the presence of three separate tumours. MRI and
MRS, biopsy with histopathological and PCR analysis are needed
for diagnosis. Optimal timing of surgery versus imaging surveil-
lance only remains controversial, though with advances in
imaging, neurosurgical techniques and other neuro-oncological
treatments (radiotherapy and chemotherapy), and recognition
that these tumours have the potential to transfer to high grade in
time, supports an increasingly aggressive surgical approach.11
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